Myriad Genetics logo

Myriad GeneticsNASDAQ: MYGN

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 October 1995

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.52 B
-42%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-41%vs. 3y high
58%vs. sector
-56%vs. 3y high
36%vs. sector

Price

pre-market | 20 min ago
$16.67+$1.55(+10.25%)

Dividend

No data over the past 3 years
$213.30 M$213.56 M
$213.30 M-$22.10 M

Analysts recommendations

Institutional Ownership

MYGN Latest News

MYGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Myriad Genetics, Inc. Shareholders Who Lost Money
accesswire.com17 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
globenewswire.com17 November 2024 Sentiment: NEGATIVE

NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - MYGN
accesswire.com17 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accesswire.com17 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
accesswire.com15 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

Shareholders that Lost Money on Myriad Genetics, Inc. (MYGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - MYGN
accesswire.com13 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

Did Myriad Genetics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - MYGN
accesswire.com13 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

Myriad Genetics, Inc. (MYGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

Myriad Genetics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - MYGN
accesswire.com11 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.

What type of business is Myriad Genetics?

Myriad Genetics, Inc. is one of the largest specialized molecular diagnostic laboratories in the world. Founded in 1992, the headquarters is located in Salt Lake City, Utah. The company uses a range of patented technologies, including DNA, RNA, and protein analysis, to help understand the genetic basis of human diseases and the role that genes and their associated proteins may play in the onset and progression of disease. The company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests designed to assess individual risk of developing disease in old age, determine the likelihood of a patient's response to drug therapy and dosage for the patient, or assess the risk of disease progression and recurrence.

What sector is Myriad Genetics in?

Myriad Genetics is in the Healthcare sector

What industry is Myriad Genetics in?

Myriad Genetics is in the Diagnostics & Research industry

What country is Myriad Genetics from?

Myriad Genetics is headquartered in United States

When did Myriad Genetics go public?

Myriad Genetics initial public offering (IPO) was on 06 October 1995

What is Myriad Genetics website?

https://www.myriad.com

Is Myriad Genetics in the S&P 500?

No, Myriad Genetics is not included in the S&P 500 index

Is Myriad Genetics in the NASDAQ 100?

No, Myriad Genetics is not included in the NASDAQ 100 index

Is Myriad Genetics in the Dow Jones?

No, Myriad Genetics is not included in the Dow Jones index

When was Myriad Genetics the previous earnings report?

No data

When does Myriad Genetics earnings report?

The next expected earnings date for Myriad Genetics is 27 February 2025